1 January 2017 in International Journal of Surgery Case Reports
The 3D printing model of the intrahepatic vessels and regional anatomy are often used for navigation surgery. Here, we report the use of the model for anatomical resection of hepatocellular carcinoma. Case 1: A tumor, 31mm in diameter, was located in segment 7 of the liver. Using the 3D model, we identified the regional Glissonian pedicle and performed resection of segment 7. Case 2: The tumor was located in segment 4/8 and involved the middle hepatic vein. Radical resection of segment 4 and of the ventral area of the right anterior section was performed using the 3D model. The positional relationship between the intrahepatic vessels and liver tumors is the most important factor for anatomical resection for hepatocellular carcinoma. Therefore our simplified 3D model of intrahepatic vessels without liver parenchyma is sufficient for effective guidance during surgery and has the advantage of being feasible to use for all HCC surgeries. Use of 3D printed models might have many merits and contribute to the great improvement of the surgical quality.
20 September 2019 in Annals of Gastroenterological Surgery
Aim: Although inflammation‐based markers in cancer have been used for prognostic prediction, the most useful marker for hepatocellular carcinoma (HCC) has not been established. We investigated the usefulness of various inflammation‐based markers in HCC patients after hepatectomy.Methods: A total of 478 patients who underwent initial hepatectomy for HCC from 2009 to 2015 and were diagnosed with pathological HCC were included in this retrospective study. Inflammation‐based markers consisted of the C‐reactive protein to albumin ratio (CAR), Glasgow prognostic score (GPS), neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, platelet to lymphocyte ratio and prognostic index. Univariate and multivariate analyses for overall survival (OS) and disease‐free survival (DFS) using the Cox proportional hazard model were carried out. Kaplan‐Meier analysis and log‐rank test were used for comparison of OS and DFS. To reduce influences of selection bias and confounders for stratifying CAR, clinicopathological characteristics of patients were balanced by propensity score matching.Results: Multivariate analysis identified only high CAR (>0.027) as an indicator of poor OS, and high CAR and high GPS (1‐2) as indicators of poor DFS among inflammation‐based markers. After propensity score matching, 124 patients each with low CAR and high CAR were matched. High CAR was correlated with both poor OS and DFS.Conclusion: C‐reactive protein to albumin ratio was the most valuable prognostic indicator after hepatectomy for HCC among inflammation‐based markers.
22 December 2014 in Liver Transplantation
30 August 2019 in Surgery Today
17 October 2015 in Surgical Case Reports
Pseudolymphoma is a benign lymphocytic tumor-like lesion, and its occurrence in the liver is rare. Here, we report the case of a 78-year-old woman with pseudolymphoma of the liver. She had a history of tremors for several years. Therefore, she underwent computed tomography (CT) for screening, and liver tumors were incidentally identified. She did not have any history of liver disease. Liver function test results and tumor marker levels were all within normal limits, and viral markers for hepatitis were negative. Contrast-enhanced CT revealed four nodules measuring up to 13 mm in diameter with ring enhancement in both lobes of the liver. On magnetic resonance imaging, the lesions showed slightly high intensity on T2-weighted images and high intensity on diffusion-weighted images. Because of atypical imaging findings, the tumors could not be definitively diagnosed. Therefore, we performed laparoscopic limited resection of segments 2, 3, 4, and 8 of the liver. The final pathological diagnosis was pseudolymphoma of the liver. The patient has had no signs of recurrence for 6 months after the surgery. Although pseudolymphoma of the liver is rare, it is necessary to consider it in the differential diagnosis of a liver tumor.
23 January 2019 in Hepatology Research